Asianet Newsable on MSN
Can IBRX stock snap its 4-day slide? Founder promises ‘game-changer’ Anktiva data as FDA speeds drug reviews
The founder cited remarks from a former FDA official and an NIH Director supporting mechanism-based review to speed patient access to therapies like Anktiva.
Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results